Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives (Q37769104)

22 August 2017

1 reference

title

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives (English)

1 reference

22 August 2017

0 references

0 references

12

Henrik Zetterberg

1 reference

22 August 2017

1

Harald Hampel

1 reference

22 August 2017

14

Kaj Blennow

1 reference

22 August 2017

4

Stefan J Teipel

1 reference

22 August 2017

6

John Hardy

1 reference

22 August 2017

13

Janet Woodcock

1 reference

22 August 2017

8

Arun L W Bokde

1 reference

22 August 2017

3

Karl Broich

1 reference

22 August 2017

7

Karl Herholz

1 reference

22 August 2017

9

Frank Jessen

1 reference

22 August 2017

Richard Frank

2

1 reference

22 August 2017

Russell G Katz

series ordinal

5

1 reference

22 August 2017

Yvonne C Hoessler

series ordinal

10

1 reference

22 August 2017

Wendy R Sanhai

series ordinal

11

1 reference

22 August 2017

1 July 2010

1 reference

Nature Reviews Drug Discovery

22 August 2017

1 reference

22 August 2017

9

1 reference

22 August 2017

560-574

1 reference

22 August 2017

7

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd3115

22 August 2017

0 references

1 reference

Therapeutic approaches to Alzheimer's disease

31 March 2020

1 reference

Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575.

31 March 2020

1 reference

Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition.

31 March 2020

1 reference

Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model

31 March 2020

1 reference

Forecasting the global burden of Alzheimer’s disease

31 March 2020

1 reference

How can we recognize "disease modification" effects?

31 March 2020

1 reference

Clinical biomarkers in drug discovery and development

31 March 2020

1 reference

Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease

31 March 2020

1 reference

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

31 March 2020

1 reference

CSF markers for incipient Alzheimer's disease

31 March 2020

1 reference

Novel MRI techniques in the assessment of dementia

31 March 2020

1 reference

Core candidate neurochemical and imaging biomarkers of Alzheimer's disease

31 March 2020

1 reference

The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews

31 March 2020

1 reference

The neural basis of the blood-oxygen-level-dependent functional magnetic resonance imaging signal

31 March 2020

1 reference

The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man

31 March 2020

1 reference

PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis

31 March 2020

1 reference

Mild cognitive impairment: believe it or not?

31 March 2020

1 reference

Structural Neuroimaging in the Detection and Prognosis of Pre-Clinical and Early AD

31 March 2020

1 reference

Reliability of cerebral measures in repeated examinations with magnetic resonance imaging.

31 March 2020

1 reference

Multicenter assessment of reliability of cranial MRI.

31 March 2020

1 reference

Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild Alzheimer disease: a functional magnetic resonance imaging study

31 March 2020

1 reference

N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology

31 March 2020

1 reference

1H magnetic resonance spectroscopy in dementia

31 March 2020

1 reference

Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies

31 March 2020

1 reference

One-year change in cerebral glucose metabolism in patients with Alzheimer's disease

31 March 2020

1 reference

Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study

31 March 2020

1 reference

Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease.

31 March 2020

1 reference

Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease

31 March 2020

1 reference

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

31 March 2020

1 reference

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment

31 March 2020

1 reference

Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography.

31 March 2020

1 reference

Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease.

31 March 2020

1 reference

PET imaging of amyloid deposition in patients with mild cognitive impairment.

31 March 2020

1 reference

Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism.

31 March 2020

1 reference

The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease.

31 March 2020

1 reference

Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders

31 March 2020

1 reference

Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the ALZHEMED (Tramiprosate) experience

31 March 2020

1 reference

Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease

31 March 2020

1 reference

Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease

31 March 2020

1 reference

Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography

31 March 2020

1 reference

Correlations between apolipoprotein E epsilon4 gene dose and whole brain atrophy rates.

31 March 2020

1 reference

Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI.

31 March 2020

1 reference

Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

31 March 2020

1 reference

A survey of genetic human cortical gene expression

31 March 2020

1 reference

Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta

31 March 2020

1 reference

Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition

31 March 2020

1 reference

A genome-wide association study identifies protein quantitative trait loci (pQTLs)

31 March 2020

1 reference

Global pharmacogenetics: genetic substructure of Eurasian populations and its effect on variants of drug-metabolizing enzymes

31 March 2020

1 reference

Statement on Use of Apolipoprotein E Testing for Alzheimer Disease

31 March 2020

1 reference

Disclosure of APOE genotype for risk of Alzheimer's disease

31 March 2020

1 reference

CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI.

31 March 2020

1 reference

Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins

31 March 2020

1 reference

Biomarkers of Alzheimer disease in plasma

31 March 2020

1 reference

Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma.

31 March 2020

1 reference

Safety and acceptability of the research lumbar puncture.

31 March 2020

1 reference

Cerebrospinal fluid protein biomarkers for Alzheimer's disease

31 March 2020

1 reference

CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study.

31 March 2020

1 reference

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

31 March 2020

1 reference

CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.

31 March 2020

1 reference

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

31 March 2020

1 reference

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.

31 March 2020

1 reference

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

31 March 2020

1 reference

Aspects of beta-amyloid as a biomarker for Alzheimer's disease

31 March 2020

1 reference

Current state and future directions of neurochemical biomarkers for Alzheimer's disease

31 March 2020

1 reference

Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment.

31 March 2020

1 reference

Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease

31 March 2020

1 reference

Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease

31 March 2020

1 reference

Muscarinic acetylcholine receptors activate expression of the EGR gene family of transcription factors

31 March 2020

1 reference

Longitudinal stability of CSF biomarkers in Alzheimer's disease.

31 March 2020

1 reference

Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years.

31 March 2020

1 reference

Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[

31 March 2020

1 reference

Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897.

31 March 2020

1 reference

Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease

31 March 2020

1 reference

First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates

31 March 2020

1 reference

Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta

31 March 2020

1 reference

Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

31 March 2020

1 reference

Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.

31 March 2020

1 reference

Neurochemical aftermath of amateur boxing.

31 March 2020

1 reference

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

31 March 2020

1 reference

Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease.

31 March 2020

1 reference

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

31 March 2020

1 reference

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

31 March 2020

1 reference

Early risk assessment for Alzheimer's disease

31 March 2020

1 reference

Antecedent biomarkers of Alzheimer's disease: the adult children study.

31 March 2020

1 reference

[11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease

31 March 2020

1 reference

The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint

31 March 2020

1 reference

Phases of biomarker development for early detection of cancer

31 March 2020

1 reference

The FDA critical path initiative and its influence on new drug development.

31 March 2020

1 reference

Biomarkers and surrogate markers: an FDA perspective

31 March 2020

1 reference

Are surrogate markers adequate to assess cardiovascular disease drugs?

31 March 2020

1 reference

A perfect correlate does not a surrogate make

31 March 2020

1 reference

Surrogate end points in clinical trials: are we being misled?

31 March 2020

1 reference

Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

31 March 2020

1 reference

The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods

31 March 2020

1 reference

Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI).

31 March 2020

1 reference

A cost-effectiveness approach to the qualification and acceptance of biomarkers

31 March 2020

1 reference

The US Food and Drug Administration perspective on cancer biomarker development.

31 March 2020

1 reference

A critical path approach to advance nanoengineered medical products

31 March 2020

1 reference

Application of automated medial temporal lobe atrophy scale to Alzheimer disease.

31 March 2020

1 reference

Accuracy and reproducibility of brain and tissue volumes using a magnetic resonance segmentation method.

31 March 2020

1 reference

Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease

31 March 2020

1 reference

Prediction of Alzheimer's disease in mild cognitive impairment: a prospective study in Taiwan.

31 March 2020

1 reference

Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects.

31 March 2020

1 reference

Within-session and between-session reproducibility of cerebral sensorimotor activation: a test--retest effect evidenced with functional magnetic resonance imaging.

31 March 2020

1 reference

Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation--a pharmacological fMRI study

31 March 2020

1 reference

Reduced medial temporal lobe N-acetylaspartate in cognitively impaired but nondemented patients

31 March 2020

1 reference

Treatment monitoring and response prediction with proton MR spectroscopy in AD

31 March 2020

1 reference

Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study.

31 March 2020

1 reference

Effect of piracetam on cerebral glucose metabolism in Alzheimer's disease as measured by positron emission tomography.

31 March 2020

1 reference

Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer's disease: a double-blind cross-over trial.

31 March 2020

1 reference

Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.

31 March 2020

1 reference

Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease.

31 March 2020

1 reference

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

31 March 2020

1 reference

Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

31 March 2020

1 reference

Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients.

31 March 2020

1 reference

Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.

31 March 2020

1 reference

Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau.

31 March 2020

1 reference

Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.

31 March 2020

1 reference

Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease.

31 March 2020

1 reference

Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment.

31 March 2020

1 reference

Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment.

31 March 2020

1 reference

Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients

31 March 2020

1 reference

Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay.

31 March 2020

1 reference

CSF BACE1 activity is increased in CJD and Alzheimer disease versus [corrected] other dementias.

31 March 2020

1 reference

Increased beta-Secretase activity in cerebrospinal fluid of Alzheimer's disease subjects.

31 March 2020

1 reference

Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease

31 March 2020

1 reference

Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies.

31 March 2020

1 reference

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization.

31 March 2020

1 reference

Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients.

31 March 2020

1 reference

Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study

31 March 2020

1 reference

Long-term effects of phosphatidylserine, pyritinol, and cognitive training in Alzheimer's disease. A neuropsychological, EEG, and PET investigation.

31 March 2020

1 reference

12 December 2020

Hippocampal pathology reflects memory deficit and brain imaging measurements in Alzheimer's disease: clinicopathologic correlations using three sets of pathologic diagnostic criteria.

1 reference

12 December 2020

Comparability of FDG PET studies in probable Alzheimer's disease

1 reference

12 December 2020

Slowing the progression of Alzheimer disease: methodologic issues.

1 reference

12 December 2020

Cortical activation during cholinesterase-inhibitor treatment in Alzheimer disease: preliminary findings from a pharmaco-fMRI study.

1 reference

12 December 2020

Structural neuroimaging in the detection and prognosis of pre-clinical and early AD.

1 reference

12 December 2020

Statement on use of apolipoprotein E testing for Alzheimer disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer disease

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD3115

1 reference

22 August 2017

1 reference